DekaBank Deutsche Girozentrale boosted its position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 23.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,500 shares of the biopharmaceutical company’s stock after purchasing an additional 2,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Puma Biotechnology were worth $461,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. NumerixS Investment Technologies Inc raised its stake in Puma Biotechnology by 969.5% during the fourth quarter. NumerixS Investment Technologies Inc now owns 2,139 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,939 shares during the period. Advisor Group Inc. raised its stake in Puma Biotechnology by 85.0% during the first quarter. Advisor Group Inc. now owns 1,554 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 714 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in Puma Biotechnology during the fourth quarter worth about $61,000. Acadian Asset Management LLC purchased a new position in Puma Biotechnology during the first quarter worth about $178,000. Finally, Metropolitan Life Insurance Co. NY raised its stake in Puma Biotechnology by 383.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,698 shares of the biopharmaceutical company’s stock worth $197,000 after purchasing an additional 7,690 shares during the period. 86.80% of the stock is currently owned by institutional investors.
Puma Biotechnology stock opened at $13.49 on Thursday. The company has a market capitalization of $520.88 million, a PE ratio of -4.51 and a beta of 1.16. Puma Biotechnology Inc has a 1 year low of $13.15 and a 1 year high of $65.45. The company has a current ratio of 2.53, a quick ratio of 2.50 and a debt-to-equity ratio of 4.08.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.43. The firm had revenue of $99.10 million during the quarter, compared to analysts’ expectations of $67.25 million. Puma Biotechnology had a negative net margin of 35.01% and a negative return on equity of 245.22%. The business’s quarterly revenue was up 49.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 earnings per share. On average, research analysts forecast that Puma Biotechnology Inc will post -2.22 EPS for the current year.
A number of equities analysts have commented on PBYI shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $57.00 target price on shares of Puma Biotechnology in a research note on Thursday, February 28th. Citigroup boosted their price target on shares of Puma Biotechnology from $67.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Cowen reissued a “hold” rating and issued a $68.00 price target on shares of Puma Biotechnology in a research note on Friday, March 1st. JPMorgan Chase & Co. reissued a “sell” rating and issued a $27.00 price target on shares of Puma Biotechnology in a research note on Sunday, March 3rd. Finally, BidaskClub downgraded shares of Puma Biotechnology from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. Five analysts have rated the stock with a sell rating and eight have given a hold rating to the company. Puma Biotechnology has an average rating of “Hold” and an average target price of $26.89.
TRADEMARK VIOLATION NOTICE: “DekaBank Deutsche Girozentrale Has $461,000 Holdings in Puma Biotechnology Inc (NASDAQ:PBYI)” was posted by Modern Readers and is the sole property of of Modern Readers. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.modernreaders.com/news/2019/06/13/dekabank-deutsche-girozentrale-has-461000-holdings-in-puma-biotechnology-inc-nasdaqpbyi.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).
See Also: Cost of Capital
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.